AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04182555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilirubin estimates from Smartphone Application
Description: Bilirubin estimates through color analysis of digital images obtained through smartphone application.
Study NCT02480712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg fixed-dose combination (FDC) tablet administered orally once daily
Study NCT02582762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nail gel
Description: apply nail gel on affected nails twice daily for 2 months
Study NCT03771547 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ERCP
Study NCT02933970 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine
Description: Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member
Study NCT04182555 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bilirubin concentration measured in standard blood samples
Description: Bilirubin measured in total serum bilirubin.
Study NCT04182555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilirubin estimates from standard transcutaneous device
Description: Bilirubin estimates performed by transcutaneous device ( Dräger JM-105)
Study NCT04182555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual assessment of jaundice
Description: Degree of jaundice will be assessed by Kramer scale
Study NCT04097444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT04097444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Given IV
Study NCT04097444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Description: Given IV
Study NCT04097444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride
Description: Given IV
Study NCT04097444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT03515603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic resection
Description: Transsphenoidal endoscopic resection of pituitary adenoma
Study NCT03515603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microsurgical resection
Description: Transsphenoidal microsurgical resection of pituitary adenoma
Study NCT02284334 — intervention group
Intervention type: OTHER
Intervention: test meal
Description: low- or high-glycemic index test meal, administered during mixed meal tolerance test
Study NCT01605396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, \& 22-26 of 28-day cycle.
Study NCT01605396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ridaforolimus
Description: Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, \& 22-26 of 28-day cycle.
Study NCT01605396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: Dalotuzumab administered 10 mg/kg IV weekly on Days 1, 8, 15, and 22 of 28-day cycle.
Study NCT01605396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg tablet administered PO QD.
Study NCT01605396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane 25 mg tablet administered PO QD.
Study NCT02758886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal assisted activity
Description: Allowed to interact (e.g. talking, petting, scratching, feeding treats, playing with) live animals
Study NCT02758886 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Animal photos
Description: A 10 minute, silent, PowerPoint slide show of a variety of dogs and cats
Study NCT02758886 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Observing human-animal interaction
Description: Participants watched others participate in petting dogs and cats, while they waited in line for 10 minutes. Participants did not physically touch any animals during this time.
Study NCT03204838 — intervention group
Intervention type: GENETIC
Intervention: IDH mutation test performed at diagnosis
Description: Observation of the test result
Study NCT02429596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Switch from brand to generic
Study NCT04747574 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: EXO-CD24
Description: The study active treatment is EXO-CD24 -exosomes (natural nano-sized vesicles secreted by human cells) that were engineered to overexpress CD24, aerosolized in normal saline for inhalation via a standard hospital-grade inhalation device, QD for 5 days.
Study NCT02826044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP2086
Description: The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.
Study NCT01564290 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic yogurt
Description: Lactobacilus Rhamnonsus 100000000 UFC per mL. Dosage 50 mL twice daily fo 5 days.
Study NCT01564290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo probiotic
Description: Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
Study NCT01592851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride
Description: dentifrice containing stannous fluoride
Study NCT01592851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Monofluorophosphate
Description: dentifrice containing Sodium Monofluorophosphate
Study NCT03321786 — intervention group
Intervention type: OTHER
Intervention: The University of Pennsylvania Smell Identification Test (UPSIT)
Description: This standardized test, the most widely used olfactory test in the world, is derived from basic psychological test measurement theory and focuses on the comparative ability of subjects to identify odorants at the suprathreshold level. The UPSIT consists of four envelope-sized booklets, each containing ten scratch and sniff odorants embedded in 10- 50-µm polymer microcapsules positioned on brown strips at the bottom of the pages of the booklets.
Study NCT01506414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO in combination with Rituximab
Description: Rituximab was given intravenously at a dose of 100 mg weekly for 4 consecutive weeks (Day 1, 8, 15, 22). Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration) was given subcutaneously at a dose of 1.0 μg/kg（300u/kg）for 14 days (Day 1-14).
Study NCT00778752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid (Lenalidomide)
Description: 3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall.~If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall.~If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials.
Study NCT01401426 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic vertical sleeve gastrectomy
Description: Laparoscopic vertical sleeve gastrectomy for the treatment of morbid obesity.
Study NCT01401426 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic vertical sleeve gastrectomy
Description: Laparoscopic vertical sleeve gastrectomy
Study NCT01073956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medium-wave 448 kHz therapy
Description: 0.5 MHz radiofrequency for 10 minutes. At SPS insertion and bicipital groove
Study NCT01073956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic therapy
Description: Pulsed 1 MHz ultrasound at 2 W/cm2 for 10 minutes. At SPS insertion and bicipital-groove
Study NCT01073956 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive electrotherapy
Description: Inactive electrotherapy, inactive head, dosage 0 W/cm2 for 10 minutes. At SPS insertion and bicipital groove.
Study NCT04097444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT01940159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SEP-363856
Description: SEP-36385625 as a single oral dose of 25, 50, 100, and 150 mcg
Study NCT01940159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose placebo
Study NCT01942278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BHOMA
Description: A complex health systems, clinical care, and community intervention to improve outcomes
Study NCT01919827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endobronchial infusion of adult mesenchymal stem cells
Study NCT01919827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells derived from bone marrow
Study NCT02582554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NutriSTEP
Description: Provision of nutrition risk screening with NutriSTEP (a nutrition risk screening questionnaire for preschoolers) and nutrition education with NutriSTEP related materials
Study NCT03709888 — intervention group
Intervention type: DRUG
Intervention: Memantine XR-pregabalin combination therapy
Description: Pregabalin and memantine XR work in different pathways and are approved by the U.S. Food and Drug Administration for various indications. Both medications have an established safety profile and have demonstrated improvement on neuropathy-related symptoms.
Study NCT01572532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening treatment and referral
Description: Women who are symptomatic at any study visit will be immediately referred to the sub-district hospital for full evaluation and treatment and will be visited on the following day to follow clinical status and ensure referral compliance. Referral will be reinforced by arranging transportation to the sub-district hospital and payment of hospital fees if the family is unable to afford out-of-pocket expenses. CHWs will conduct a home visit to women with positive test results within 24 hours of receiving the results to initiate treatment. All asymptomatic women will be treated for positive test results. For symptomatic women, the CHW will confirm the woman's clinical and treatment status, and provide treatment to those women who have not already received the appropriate treatment at the sub-district hospital for their infection.~Antibiotic Treatment Regimens AVF: Oral clindamycin 300 mg per oral (po) twice daily (bid) for 5 days.UTI: Macrobid/Nitrofurantoin 100 mg po bid x 7 days.
Study NCT03699982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily calorie target based on resting energy expenditure
Description: Resting Energy Expenditure will be determined using the Harris-Benedict formula and indirect calorimetry testing. Additionally, a 48 Hour Dietary Recall will be completed to estimate approximate caloric intake at baseline.~Participants will be instructed to increase their daily calorie intake based on the highest REE/caloric intake, whether by indirect calorimetry, the Harris-Benedict formula, or patient's estimated current caloric intake.
Study NCT04045613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg once daily monotherapy
Description: Derazantinib was administered orally at a dose of 300 mg once daily
Study NCT04045613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 200 mg once daily + atezolizumab 1200 mg
Description: Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
Study NCT04045613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg once daily+ atezolizumab 1200 mg
Description: Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
Study NCT04045613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 200 mg twice daily + atezolizumab 1200 mg
Description: Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks
Study NCT04045613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg once daily monotherapy (QD)
Description: Derazantinib was administered orally at a dose of 300 mg once daily
Study NCT04045613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg once daily + atezolizumab 1200 mg
Description: Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
Study NCT04045613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib 200 mg twice daily monotherapy
Description: Derazantinib was administered orally at a dose of 200 mg twice daily
Study NCT01221467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Overnight closed-loop
Description: The closed-loop system is purpose-built and comprises a hand-held computer containing the algorithm and communicating with the CGM device and the insulin pump.
Study NCT03300648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Description: Intubation and mechanical ventilation for a maximum of 7 days
Study NCT03300648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: Intravenous 3 percent hypertonic saline for a maximum of 7 days
Study NCT02910375 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cohort A
Description: Venous sampling (n=13) will be performed in the hospital at D0 (prior to first golimumab injection), D3, D7, D14 (prior to second injection), D28, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D3, M1D7, M2D0 (8 weeks after M0D0, week 14), M3D0 (12 weeks after M0D0, week 18) Dried blood spot sampling (n=39) will be performed at D0 (prior to first golimumab injection), D1, D2, D3, D4, D5, D6, D7, D10, D14, D15, D16, D17, D18, D19, D20, D21, D28, D35, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, rig week 14), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, week 18)
Study NCT02910375 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cohort B
Description: Venous sampling (n=8) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D3, M1D7, M2D0 (8 weeks after M0D0, right before next injection), M3D0 (12 weeks after M0D0, right before next injection) Dried blood spot sampling (n=20) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, right before next injection), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, right before next injection)
Study NCT01098955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: 6 x 60-minute counseling sessions delivered over a 5-week period
Study NCT04172987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT04172987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/NGM
Description: Combination oral contraceptive administered orally
Study NCT01098955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational and Behavioral Counseling
Description: 6 x 60-minute counseling sessions delivered over a 5-week period
Study NCT00761774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Subjects will begin at a recommended dose of Brivaracetam 100 mg/day. Subjects will continue treatment at a dose up to a maximum of 200 mg/day with a twice per day administration. Up- and down-titration steps may be performed in steps of a maximum of 50 mg/day on a weekly basis. Full down-titration should include a one week step on 20 mg/day. The study medication will come in 10 mg and 25 mg tablet strengths.
Study NCT01201564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraperitoneal onlay mesh repair
Description: The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
Study NCT01201564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sublay mesh repair
Description: The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
Study NCT01098955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 2 mg daily for 12 weeks
Study NCT02135601 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water colonoscopy
Description: Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
Study NCT02947763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mixture of metronidazole, ciprofloxacin, and minocycline
Description: placement of intracanal medication
Study NCT04051593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical stabilization exercise
Description: The participants followed instructional videos and performed the cervical stabilization exercise program at home for 20 minutes/day, 3 days/week, for 6 weeks.
Study NCT04651231 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: releasable sutures in punch trabeculectomy
Description: punch trabeculectomy,scleral flap suturing
Study NCT03408873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abilify Maintena
Description: Drug is in an injectable form and will be administered approximately every four weeks through Week 24 of the study. Dosage is per package insert or at the discretion of the psychiatrist.
Study NCT03408873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized Adherence Enhancement (CAE)
Description: CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
Study NCT04546412 — intervention group
Intervention type: DEVICE
Intervention: Vitrification and thawing
Description: Vitrification using the Cryotop® - Open System followed by thawing
Study NCT02856776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D provided in capsule form
Study NCT04651231 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: releasable sutures in punch trabeculectomy
Description: punch trabeculectomy,scleral flap suturing
Study NCT02932111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteopathic session
Description: 3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
Study NCT02932111 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo manipulative session
Description: 3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
Study NCT03498261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin has been commonly used as an adjuvant in the treatment of neuropathic pain.
Study NCT03498261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo
Study NCT01218685 — intervention group
Intervention type: BIOLOGICAL
Intervention: Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS
Description: 1 full dose of 15 micrograms, IM, for volunteers 9 years of age or older; children 6 months to 2 years of age, half of the dose,IM, with 21 days interval; children 3 years old up to 8 years old, 1 full dose, IM, twice, with 21 days interval.